Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The New World for New Drug Approvals: Evolution in Strategies for Getting FDA Drug Approvals

This article was originally published in RPM Report

Executive Summary

Pharma is adjusting rapidly to a new regulatory world: one in which post-marketing risk management plans change the relationship of the company to doctors and patients and one where FDA's expectations for pre-marketing information about product markets are likely to expand dramatically.

Related Content

Living With REMS: The New Regulatory Model Meets Commercial Reality
The Impact of FDAAA On Drug Approvals: Setting the Baseline
Psychiatric Adverse Events: Navigating a New Drug Safety Landmine
Cervarix Delayed: Setback for GSK is Opportunity for FDA to Create New Model for Adjuvant Approvals
Relabeling EPO: Closing the Books on a Safety Issue, Opening a New Chapter at FDA
Straight Talk from FDA: Wyeth R&D Head Reacts to Climate Change for NDA/BLA Reviews
The Data Everybody's Talking About: Proof FDA is More Conservative?
The Second Coming: Tysabri Ready For Blockbuster Status?
Tysabri: The Risk of Revival
Building a Business in Drug Safety


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts